• Login
    • Login
    Advanced Search
    View Item 
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Miniature, low-dose, intrauterine drug-delivery systems.

    Thumbnail
    View/Open
    ABSTRACT.pdf (16.71Kb)
    Date
    2003-11
    Author
    Wildemeersch, D
    Dhont, M
    Weyers, S
    Temmerman, M
    Type
    Article
    Language
    en
    Metadata
    Show full item record

    Abstract
    The safety of systemically administered sex steroids continues to be a major focus of researchers. The negative results of the Women's Health Initiative study (WHI), and follow-up reports published in JAMA, evaluating the safety of estro-progestogen in postmenopausal women, elicited an unprecedented reaction in the press by women and doctors alike. From these publications, it is clear that research should focus on new progestogens and on alternative administration routes to minimize adverse drug effects. One approach to the improvement of safety, efficacy, and acceptability of steroid hormones, including patient compliance, is to develop long-acting implantable methods that deliver the lowest possible dose to the key target tissues. This therapeutic concept of "minimal intervention" has been known for several decades, but the practical applications of the method were lacking. Intrauterine drug-delivery systems can be developed to achieve minimal intervention fertility control without influencing normal ovarian function and/or causing adverse hormonal effects. With hormone replacement therapy in postmenopausal women, research suggests that progestogens delivered directly to the uterine mucosa could reduce side effects and minimize reversal of the beneficial effect of estrogens. Various "frameless" and "framed" intrauterine systems are currently being clinically evaluated. They are less troublesome than the available intrauterine systems and could therefore be suitable for use in the majority of women for contraception and treatment purposes (e.g., menorrhagia, hormone replacement). These systems require a single short office procedure, and have a low morbidity, which is undeniably linked with more invasive methods and systemic hormonal contraceptives. Due to the technological progress miniature, low-dose, long-term intrauterine drug-delivery systems offer enhanced effectiveness, reduced side effects, and optimal user compliance. Although there is minimal absorption in the systemic circulation, they deserve the status of a locally acting method that should be regarded as fundamentally advantageous, if effective, to systemically applied medications that may have potentially inherent ill side effects
    URI
    http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/14644824
    http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/40601
    Citation
    Ann N Y Acad Sci. 2003 Nov;997:174-84.
    Publisher
    University of Nairobi.
     
    College of Health Sciences
     
    Collections
    • Faculty of Health Sciences (FHS) [10418]

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback

     

     

    Useful Links
    UON HomeLibrary HomeKLISC

    Browse

    All of UoN Digital RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback